Tel-Aviv Sourasky Medical Center

Tel Aviv, Tel Aviv 6423906

2 studies enrolling now · 9 studies all time

What they study most

Anemia, Cardiovascular Disease, Gastric Cancer, Gastroesophageal Junction Cancer, Glioblastoma Multiforme, Mild Thrombocytopenia, Moderate Thrombocytopenia, Myelodysplastic Syndromes, Myelofibrosis, Myeloproliferative Disorders, Obstructive Hypertrophic Cardiomyopathy, Pancreatic Ductal Carcinoma

Studies at this site

• PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort — Recruiting now
• A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia — Recruiting now
• Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) — Running, not enrolling
• An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions — Running, not enrolling
• Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM — Completed
• A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer — Completed
• Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy — Completed
• A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma — Stopped early
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early